Novel PD-L1/VISTA Dual Inhibitor as Potential Immunotherapy Agents
Journal of Medicinal Chemistry · 09.01.2025 · 68 (1) · 156-173
DOI: 10.1021/acs.jmedchem.4c01640 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 28.12.2024. Verfasst von Chengliang Sun und 14 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Natural Medicines and Jiangsu Key Laboratory of Drug Design and Optimization, China Pharmaceutical University, Nanjing 210009…. Hauptthemen laut MEDLINE: B7-H1 Antigen, Immunotherapy. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 38 Literaturangaben. Gefördert von: National Key Research and Development Program of China, China Postdoctoral Science Foundation, Fundamental Research Funds for the Central Universities.
Abstract (Originalsprache)
Inhibiting the activity of immune checkpoint proteins to reignite the antitumor activity of immune cells has emerged as a pivotal strategy. PD-L1 and VISTA, as critical proteins governing immune regulation, are concurrently upregulated under conditions such as hypoxia. Through a rational drug design process, P17, a dual-target inhibitor for PD-L1 and VISTA is identified. This inhibitor blocks the signaling pathways of both PD-L1 and VISTA at the protein and cellular levels, thereby reactivating the antitumor function of T cells. P17 displays encouraging attributes in terms of druggability and safety assessments. Notably, P17 demonstrates superior antitumor efficacy compared to single-target inhibitors at equivalent doses in in vivo experiments. More crucially, P17 significantly enhances the infiltration of immune cells. This study not only validates the effectiveness of a dual-target inhibitor strategy against PD-L1 and VISTA, but also identifies P17 as a promising candidate molecule with significant therapeutic potential.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Natural Medicines and Jiangsu Key Laboratory of Drug Design and Optimization, China Pharmaceutical University, Nanjing 210009, China.
- Department of Medicinal Chemistry, School of Pharmacy, China Pharmaceutical University, Nanjing 211198, China.
- Institute of Innovative Drug Discovery and Development, China Pharmaceutical University, Nanjing 211198, China.
- Department of Pharmacology, School of Pharmacy, China Pharmaceutical University, Nanjing 211198, China.
- Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100050, China.
- School of Biomedical Sciences, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong SAR 999077, China.
ORCID-Profile: Hongbin Deng, Peng Yang
Förderung
- National Key Research and Development Program of China
- China Postdoctoral Science Foundation
- Fundamental Research Funds for the Central Universities
- National Natural Science Foundation of China
- Jiangsu Distinguished Postdoctoral Program
- CAMS Innovation Fund for Medical Sciences
Zitieren
APA
Sun, C., Cheng, Y., Dong, J., Hu, L., Zhang, Y., Shen, H., Zhang, G., Jiang, B., Adam Youssouf, S., Min, W., Shen, Y., Wang, L., Deng, H., Xiao, Y., & Yang, P. (2025). Novel PD-L1/VISTA Dual Inhibitor as Potential Immunotherapy Agents. Journal of Medicinal Chemistry, 68(1), 156-173. https://doi.org/10.1021/acs.jmedchem.4c01640
Vancouver
Sun C, Cheng Y, Dong J, Hu L, Zhang Y, Shen H, et al. Novel PD-L1/VISTA Dual Inhibitor as Potential Immunotherapy Agents. Journal of Medicinal Chemistry. 2025;68(1):156-173. doi:10.1021/acs.jmedchem.4c01640
BibTeX
@article{Sun2025,
author = {Sun, Chengliang and Cheng, Yao and Dong, Jingwen and Hu, Lingrong and Zhang, Yu and Shen, Hao and Zhang, Guoyu and Jiang, Binjian and Adam Youssouf, Salouoi and Min, Wenjian and Shen, Yuxia and Wang, Liping and Deng, Hongbin and Xiao, Yibei and Yang, Peng},
title = {Novel PD-L1/VISTA Dual Inhibitor as Potential Immunotherapy Agents},
journal = {Journal of Medicinal Chemistry},
year = {2025},
volume = {68},
number = {1},
pages = {156--173},
doi = {10.1021/acs.jmedchem.4c01640}
}
EUVIMED